IVERIC bio, Inc. (NASDAQ:ISEE) Q4 2022 Earnings Call Transcript

Pravin Dugel: Kambiz we have not guided us to that. We obviously want to see the data. We want to see what the situation is like at that time, that’s a decision — this decision to be made down the road. But we really don’t believe that having every other month dosing really provides any kind of a competitive advantage, because we believe the physicians will treat according to what’s best for the patient, and what’s best for the patient is going to be dependent also on how often the patient can come in. And that’s going to be the primary determinant of the frequency of treatment, not what’s written in the label. And just to kind of put an emphasis on this. If you look at the anti-VEGF experience, for instance, the vast majority of us treat and extend and that’s not in any label.

So there is a history of my colleagues really doing what’s right for the patient given the particular situation regardless of what the label says. So the answer to your question is, look, I’m not really sure what we will do with the 24 month data whether it be on the label or not, that’s yet to be determined.

Operator: This concludes our question and answer session. I would like to turn the conference back over to Glenn Sblendorio for any closing remarks.

Glenn Sblendorio: Thank you, Andrew. And thanks everyone for listening this morning, and we’re very happy and pleased with our progress. And we look forward to our continued work with the FDA and our NDA filing and hopefully a potential approval in late August this year. We’re also committed as we talked about today to building a world class commercial team to be ready to engage physicians, healthcare providers and patients if ACP is approved. And finally, we look forward to having our vision loss data presented at ARVO. So you can expect continued execution from us. We always enjoy speaking to all of you, and have a great day. Bye-bye.

Operator: The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect.